Wang Xin, Mao Zhiqi, Cui Zhiqiang, Xu Xin, Pan Longsheng, Liang Shuli, Ling Zhipei, Yu Xinguang
1School of Medicine, Nankai University, Tianjin; and.
2Department of Neurosurgery, Chinese PLA General Hospital, Beijing, China.
J Neurosurg. 2019 Apr 5;132(5):1367-1375. doi: 10.3171/2019.1.JNS182555. Print 2020 May 1.
Primary Meige syndrome is characterized by blepharospasm and orofacial-cervical dystonia. Deep brain stimulation (DBS) is recognized as an effective therapy for patients with this condition, but previous studies have focused on clinical effects. This study explored the predictors of clinical outcome in patients with Meige syndrome who underwent DBS.
Twenty patients who underwent DBS targeting the bilateral subthalamic nucleus (STN) or globus pallidus internus (GPi) at the Chinese People's Liberation Army General Hospital from August 2013 to February 2018 were enrolled in the study. Their clinical outcomes were evaluated using the Burke-Fahn-Marsden Dystonia Rating Scale at baseline and at the follow-up visits; patients were accordingly divided into a good-outcome group and a poor-outcome group. Putative influential factors, such as age and course of disease, were examined separately, and the factors that reached statistical significance were subjected to logistic regression analysis to identify predictors of clinical outcomes.
Four factors showed significant differences between the good- and poor-outcome groups: 1) the DBS target (STN vs GPi); 2) whether symptoms first appeared at multiple sites or at a single site; 3) the sub-item scores of the mouth at baseline; and 4) the follow-up period (p < 0.05). Binary logistic regression analysis revealed that initial involvement of multiple sites and the mouth score were the only significant predictors of clinical outcome.
The severity of the disease in the initial stage and presurgical period was the only independent predictive factor of the clinical outcomes of DBS for the treatment of patients with Meige syndrome.
原发性梅杰综合征的特征为眼睑痉挛和口面部-颈部肌张力障碍。深部脑刺激(DBS)被认为是治疗该疾病患者的有效方法,但以往研究主要关注临床疗效。本研究探讨接受DBS治疗的梅杰综合征患者临床结局的预测因素。
选取2013年8月至2018年2月在中国人民解放军总医院接受双侧丘脑底核(STN)或内侧苍白球(GPi)DBS治疗的20例患者纳入研究。在基线和随访时使用伯克-法恩-马斯登肌张力障碍评定量表评估其临床结局;据此将患者分为良好结局组和不良结局组。分别检查年龄和病程等可能的影响因素,对具有统计学意义的因素进行逻辑回归分析以确定临床结局的预测因素。
良好结局组和不良结局组之间有4个因素存在显著差异:1)DBS靶点(STN与GPi);2)症状首发于多个部位还是单个部位;3)基线时口部的子项评分;4)随访时间(p<0.05)。二元逻辑回归分析显示,多个部位的初始受累情况和口部评分是临床结局的唯一显著预测因素。
疾病初始阶段和术前阶段的严重程度是DBS治疗梅杰综合征患者临床结局的唯一独立预测因素。